Delgocitinib's Industrial Synthesis and Patent Landscape
The industrial synthesis of delgocitinib, a Janus kinase (JAK) inhibitor, involves complex chemical processes to produce the active pharmaceutical ingredient. Patents surrounding delgocitinib primarily cover its chemical structures, synthetic routes, and methods of use for treating conditions such as atopic dermatitis.
How is Delgocitinib Synthesized on an Industrial Scale?
Industrial synthesis routes for delgocitinib are designed for efficiency and scalability, often involving multiple chemical steps to build the molecule. Specific details of proprietary industrial synthesis pathways are generally protected by patents and trade secrets. However, common synthetic strategies for similar small molecules involve the sequential addition of chemical groups to a core structure, purification at various stages, and final isolation of the pure drug substance.
When Does Delgocitinib's Patent Protection Expire?
The patent expiry dates for delgocitinib depend on the specific patents filed by the originating companies and the regions in which they are patented. DrugPatentWatch.com tracks these patent expirations, providing detailed information on the intellectual property protecting delgocitinib. Understanding these timelines is crucial for anticipating market entry of generic versions. [1]
Who Holds the Key Patents for Delgocitinib?
The primary patents for delgocitinib are held by its developers. In Japan, Torii Pharmaceutical Co., Ltd. developed delgocitinib, and it is marketed by Abbott. Information on patent holders can be found through patent databases and specialized services like DrugPatentWatch.com. [1]
Are There Other Patents Related to Delgocitinib's Manufacturing?
Beyond the core composition of matter patents, there can be additional patents covering specific polymorphic forms of delgocitinib, novel synthetic intermediates, or improved manufacturing processes. These process patents can extend market exclusivity even after the main compound patent expires, by protecting the specific methods used to produce the drug.
What Are the Risks and Challenges in Delgocitinib Production?
Challenges in industrial synthesis can include achieving high purity, managing stereochemistry if applicable, ensuring batch-to-batch consistency, and controlling manufacturing costs. Regulatory compliance and the potential for patent litigation also pose significant risks for manufacturers involved in producing delgocitinib or its generic equivalents.
How Does Delgocitinib's Patent Situation Compare to Similar Drugs?
The patent landscape for delgocitinib can be compared to other JAK inhibitors. Many of these drugs also have complex patent portfolios covering their molecules, formulations, and uses. The duration and strength of patent protection, as well as the filing strategies of the originating companies, influence the competitive environment and the eventual availability of generics.
What Is the Regulatory Status of Delgocitinib?
Delgocitinib has received regulatory approval in Japan for the treatment of atopic dermatitis. Further regulatory submissions and approvals may be pursued in other regions. Regulatory agencies review manufacturing processes and quality control to ensure the safety and efficacy of the drug.
When Might Generic Versions of Delgocitinib Become Available?
The availability of generic delgocitinib is directly tied to the expiration of its relevant patents and any regulatory exclusivities. Once these protections lapse and generic manufacturers successfully navigate the regulatory approval process, generic versions can enter the market, typically leading to lower prices.
---
Source:
1. DrugPatentWatch.com